PTC Therapeutics, Inc. (PTCT) continues to make significant progress in its pipeline. This is especially true when you consider that it has already been able to report positive interim results from ...

SOUTH PLAINFIELD, N.J., March 30, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with ...

PTC518 treatment resulted in the lowering of mutant huntingtin protein in the blood and cerebrospinal fluid. Furthermore, after 12 months of treatment, PTC518 remains safe and well tolerated. Ready to ...

SOUTH PLAINFIELD, N.J., June 21, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC518 in Huntington's disease ...

Novartis will partner with PTC Therapeutics to expand the use of PTC’s small molecule splicing platform to develop PTC’s PTC518 Huntington’s disease program and an unspecified number of related ...

PTC Therapeutics Inc. CEO Matthew Klein said the firm “achieved all we set out to [achieve] in phase II” with PTC-518 in Huntington’s disease (HD), but it wasn’t enough to excite Wall Street, as some ...

WARREN, N.J., May 5, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Okta Inc (Symbol: OKTA), where a total of 9,766 contracts have traded so far, representing ...